Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)

• Published in: Clinical infectious diseases Vol. 74; no. 8; pp. 1329 - 1337
• Main Authors: Ghamande, Shekhar, Shaver, Courtney, Murthy, Kempapura, Raiyani, Chandni, White, Heath D, Lat, Tasnim, Arroliga, Alejandro C, Wyatt, Dayna, Talbot, H Keipp, Martin, Emily T, Monto, Arnold S, Zimmerman, Richard K, Middleton, Donald B, Silveira, Fernanda P, Ferdinands, Jill M, Patel, Manish M, Gaglani, Manjusha
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 28.04.2022
• Subjects: Adolescent; Adult; Case-Control Studies; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human - epidemiology; Influenza, Human - prevention & control; Major and Commentaries; Pneumonia - epidemiology; Pneumonia - prevention & control; Seasons; Vaccination; Vaccine Efficacy; influenza vaccine effectiveness; pneumonia; hospitalization; case-control study; test-negative
• DOI: 10.1093/cid/ciab654
• ISSN: 1058-4838; 1537-6591

Abstract Background Evidence for vaccine effectiveness (VE) against influenza-associated pneumonia has varied by season, location, and strain. We estimate VE against hospitalization for radiographically identified influenza-associated pneumonia during 2015–2016 to 2017–2018 seasons in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Methods Among adults aged ≥18 years admitted to 10 US hospitals for acute respiratory illness (ARI), clinician-investigators used keywords from reports of chest imaging performed during 3 days around hospital admission to assign a diagnosis of “definite/probable pneumonia.” We used a test-negative design to estimate VE against hospitalization for radiographically identified laboratory-confirmed influenza-associated pneumonia, comparing reverse transcriptase–polymerase chain reaction–confirmed influenza cases with test-negative subjects. Influenza vaccination status was documented in immunization records or self-reported, including date and location. Multivariable logistic regression models were used to adjust for age, site, season, calendar-time, and other factors. Results Of 4843 adults hospitalized with ARI included in the primary analysis, 266 (5.5%) had “definite/probable pneumonia” and confirmed influenza. Adjusted VE against hospitalization for any radiographically confirmed influenza-associated pneumonia was 38% (95% confidence interval [CI], 17–53%); by type/subtype, it was 74% (95% CI, 52–87%) influenza A (H1N1)pdm09, 25% (95% CI, −15% to 50%) A (H3N2), and 23% (95% CI, −32% to 54%) influenza B. Adjusted VE against intensive care for any influenza was 57% (95% CI, 19–77%). Conclusions Influenza vaccination was modestly effective among adults in preventing hospitalizations and the need for intensive care associated with influenza pneumonia. VE was significantly higher against A (H1N1)pdm09 and was low against A (H3N2) and B. Vaccine effectiveness against adult acute respiratory illness hospitalization for radiographically identified laboratory confirmed influenza-associated pneumonia estimated using a test-negative design was 38% (95% confidence interval: 17-53%) during 2015-2016 to 2017-2018 in the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).